Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis

Brain

Volumn 131, Issue 12, 2008, Pages 3335-3347

  Pitzer, Claudia ^a   Krüger, Carola ^a   Plaas, Christian ^a   Kirsch, Friederike ^a   Dittgen, Tanjew ^a   Müller, Ralph ^a   Laage, Rico ^a   Kastner, Stefan ^a   Suess, Stefanie ^a   Spoelgen, Robert ^a   Henriques, Alexandre ^a   Ehrenreich, Hannelore ^b   Schäbitz, Wolf Rüdiger ^c   Bach, Alfred ^a   Schneider, Armin ^a  

^a SYGNIS Bioscience   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

ALS; Drug candidate; Functional outcome; Growth factor; Motoneuron survival

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; MALE; MOTONEURON; MOTOR PERFORMANCE; MOUSE; MUSCLE ATROPHY; MUSCLE DENERVATION; NEUROPROTECTION; NONHUMAN; OSMOTIC MINIPUMP; OVERALL SURVIVAL; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FEMALE; FILGRASTIM; HUMANS; INFUSIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR NEURONS; MUTATION; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME;

EID: 58149119552     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn243     Document Type: Article

References (42)

1. Apfel SC. Neurotrophic factor therapy-prospects and problems. Clin Chem Lab Med 2001; 39: 351-5.
2. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429: 413-7.
3. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, et al. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2006; 103: 16021-6.
4. Bendotti C, Carri MT. Lessons from models of SOD1-linked familial ALS. Trends Mol Med 2004; 10: 393-400.
5. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312: 1389-92.
6. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004; 27: 723-49.
7. Carri MT, Grignaschi G, Bendotti C. Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 2006; 27: 267-73.
8. Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, Shaw IT, et al. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn 1992; 194: 209-21.
9. Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995; 270: 12109-16.
10. Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007; 357: 775-88.
11. Fukada K, Zhang F, Vien A, Cashman NR, Zhu H. Mitochondrial proteomic analysis of a cell line model of familial amyotrophic lateral sclerosis. Mol Cell Proteomics 2004; 3: 1211-23.
12. Gibson CL, Bath PM, Murphy SP. G-CSF reduces infarct volume and improves functional outcome after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2005; 25: 431-9.
13. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-53.
14. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-5.
15. Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, Alexander BK, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci 2005; 236: 1-7.
16. Hubel K, Engert A. Clinical applications of granulocyte colony-stimulating factor: an update and summary. Ann Hematol 2003; 82: 207-13.
17. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-42.
18. Kirby J, Halligan E, Baptista MJ, Allen S, Heath PR, Holden H, et al. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 2005; 128: 1686-706.
19. Kruger C, Laage R, Pitzer C, Schabitz WR, Schneider A. The hematopoietic factor GM-CSF (Granulocyte-macrophage colony-stimulating factor) promotes neuronal differentiation of adult neural stem cells in vitro. BMC Neurosci 2007; 8: 88.
20. Kruger C, Laage R, Pitzer C, Schabitz WR, Schneider A. The hematopoietic factor GM-CSF (granulocyte-macrophage colony-stimulating factor) promotes neuronal differentiation of adult neural stem cells in vitro. BMC Neurosci 2007b; 8: 88.
21. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49: 1621-30.
22. McGeer EG, McGeer PL. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 2005; 19: 31-7.
23. Meuer K, Pitzer C, Teismann P, Kruger C, Goricke B, Laage R, et al. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem 2006; 97: 675-86.
24. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007: CD001447.
25. Miller TM, Kim SH, Yamanaka K, Hester M, Umapathi P, Arnson H, et al. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2006; 103: 19546-51.
26. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet 2007; 369: 2031-41.
27. Mohajeri MH, Figlewicz DA, Bohn MC. Selective loss of alpha motoneurons innervating the medial gastrocnemius muscle in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 1998; 150: 329-36.
28. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10: 615-22.
29. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001; 28: 131-8.
30. Schabitz WR, Schneider A. New targets for established proteins: exploring G-CSF for the treatment of stroke. Trends Pharmacol Sci 2007; 28: 157-61.
31. Schabitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, et al. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke 2003; 34: 745-51.
32. Schabitz WR, Kruger C, Pitzer C, Weber D, Laage R, Gassler N, et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab 2008; 28: 29-43.
33. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115: 2083-98.
34. Schneider A, Laage R, von Ahsen O, Fischer A, Rossner M, Scheek S, et al. Identification of regulated genes during permanent focal cerebral ischaemia: characterization of the protein kinase 9b5/MARKL1/MARK4. J Neurochem 2004; 88: 1114-26.
35. Schneider A, Wysocki R, Pitzer C, Kruger C, Laage R, Schwab S, et al. An extended window of opportunity for G-CSF treatment in cerebral ischemia. BMC Biol 2006; 4: 36.
36. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008; 9: 4-15.
37. Shavlakadze T, White JD, Davies M, Hoh JF, Grounds MD. Insulin-like growth factor I slows the rate of denervation induced skeletal muscle atrophy. Neuromuscul Disord 2005; 15: 139-46.
38. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8: 85-92.
39. Tanaka M, Kikuchi H, Ishizu T, Minohara M, Osoegawa M, Motomura K, et al. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2006; 65: 816-25.
40. Vincent AM, Sakowski SA, Schuyler A, Feldman EL. Strategic approaches to developing drug treatments for ALS. Drug Discov Today 2008; 13: 67-72.
41. Weber UJ, Bock T, Buschard K, Pakkenberg B. Total number and size distribution of motor neurons in the spinal cord of normal and EMC-virus infected mice-a stereological study. J Anat 1997; 191 (Pt 3): 347-53.
42. Zhao LR, Navalitloha Y, Singhal S, Mehta J, Piao CS, Guo WP, et al. Hematopoietic growth factors pass through the blood-brain barrier in intact rats. Exp Neurol 2007; 204: 569-73.